Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced a significant milestone in its ongoing Phase 2 clinical study, ACTIVATE (clinicaltrials.gov: NCT05819359), evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The ACTIVATE study has enrolled 273 genetically confi...